Pharma's Almanac TV
PA TV
Follow the Completed Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Follow the Completed Journey
Companies On The Road
Follow The Artist
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
2021 Cell & Gene Therapy Report
2021 Monoclonal Antibody & Recombinant Protein Market Report
2022 Sterile Drug Market Report
2022 API Market Report
2022 OSD Market Report
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
More+
Staffing
Media Kit
Roundtable
55 Articles Available
1
3
Can't find what you're looking for? Try our
advanced search
.
Unmet Needs
In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?
PAO-06-022--RT-01
What do you consider the biggest challenge that the pharma/biopharma industry currently faces?
Leadership
Q: What’s the key to being a leader in the industry?
PAO-03-022-RT-02
Milestones
Q: What important company milestone do you anticipate reaching in 2022?
PAO-03-022-RT-01
Personalized and Precision Medicine
Q: What do you see as the key innovations or technologies that will make personalized/precision medicine a reality?
PAO-12-21-RT-01
Therapeutic Progress
Q: For what therapeutic area do you think we will see the greatest progress in the coming years?
PAO-12-21-RT-02
Social Media Marketing
Q: What’s the next “big thing” on the horizon that will significantly alter the pharma/biopharma market, your operations, or the way you do business?
Evolving Technologies
Q: What do you think most differentiates the U.S. pharma/biopharma industry or the market?
Evolving Technologies
Q: How have evolving technologies like artificial intelligence (AI) and machine learning (ML) changed how you conduct research, manufacturing, or business?
PAO-06-21-RT-1
Social Media Marketing
Q: How is your organization using social media to extend your marketing efforts?
PAO-06-21-RT-2
Business Development
Q: How are you growing your business development activities in the absence of conventional trade shows and other traditional business development/marketing activities?
PAO-03-21-NI-02
COVID-19 Impacts
Q: Putting aside COVID-19 vaccines and therapeutics, what do you think will be the most significant development in the industry in 2021?
PAO-03-21-NI-01
COVID-19 Impacts
Q: What do you think is the greatest lesson learned from the COVID-19 pandemic, and what lasting impacts do you foresee over the next 5–10 years?
PAP-Q4-20-NI-006
Roundtable
Q: Although there is no such thing as a truly “crisis-proof” organization, how are you working to mitigate risks for future crises like the COVID-19 pandemic?
PAP-Q4-20-NI-007
Post COVID-19 Supply Chain
Q: How are you rethinking your supply chain and operational fitness in light of the COVID-19 pandemic?
PAP-Q3-20-NI-007
Roundtable
Q: What steps is your company taking to address drug pricing issues?
PAP-Q3-20-NI-008
COVID-19
Q: What is your perspective on how the pharma industry has responded to the COVID-19 pandemic? What lessons have been learned?
PAP-Q2-20-RT-001
Roundtable
Q: What two or three drug molecules do you identify as having had the greatest impact on society? What about on the pharmaceutical industry?
PAP-Q2-20-RT-002
M&A
Q: How would you characterize the current landscape of M&A activity in the pharmaceutical/biopharmaceutical industry?
PAP-Q1-20-NI-008
Technology
Q: What technology do you foresee leading the industry over the coming decade, both in terms of real approvals and general impact?
PAP-Q1-20-NI-009
Technology
Q: What developing technologies do you believe will have the greatest impact on the biopharma industry in 2020 and beyond?
PAP-Q4-19-NI-006
Technology
Q: What breakthrough technologies have had a transformative effect on your business this year?
PAP-Q4-19-NI-005
Manufacturing Technology
Q: How does your company manage to provide local services/support while still efficiently managing global compliance?
PAP-Q2-19-NI-006
Novel Therapies
Q: What do you identify as the greatest advances that have been achieved in recent years with respect to harmonization of pharmaceutical regulations?
PAP-Q2-19-NI-007
1
3
»
